FDA panel gives nod to six controversial peptides

An FDA advisory panel voted to recommend loosening regulations on six peptide treatments (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500), allowing compounding pharmacies to produce them for prescription use rather than unregulated online vendors. The FDA will make a final decision after the committee's recommendation, though agency scientists have raised concerns about insufficient safety and efficacy data.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.